Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II feasibility study of EP-2104R MRI imaging in venous thromboembolism
2004-004700-20Phase 2Completed
- Sponsor
- Epix Pharmaceuticals
- Start
- Feb 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EP-2104R in venous thromboembolism (VTE), sponsored by Epix Pharmaceuticals. Primary endpoint: Time-dependent thrombus signal intensity after EP-2104R injection. Started Feb 2005; status: completed.
02
Drugs
EP-2104R
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2004-004700-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004700-20.